>What happened in those eight weeks reveals something essential about the kind of company Hims has become. Even as they shook hands with Novo executives in April 2025—presumably in a conference room with aggressively modern furniture—Hims continued selling what their new partner called "illegitimate, knockoff versions" of Wegovy. These were compounded semaglutide injections sourced, according to Novo's investigation,…
Yeah, that's quite a stretch of comparison...
Questionable quality control vs brazen fraud